Quanterix Corporation is developing a novel platform for single molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research.   Our unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs.   Founded in 2007, Quanterix is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.

November 11, 2008 – Press Release
Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board [ PDF ]

September 30, 2008 – Press Release
Quanterix Corporation Awarded $185,000 Grant from the National Cancer Institute [ PDF ]

August 25, 2008 – Press Release
Quanterix Corporation Raises $15 Million in Series A Financing [ PDF ]

May 13, 2008 – In the News
Quanterix featured in the MIT Technology Review "Next Generation Diagnostics"

Career Inquiries: hr@quanterix.com
Other Inquiries: info@quanterix.com